Chemoreceptor effects on perfusion of hypoxic and atelectatic lung.

J. Newell,M. Levitsky,J. Krasney,R. Dutton

DOI: https://doi.org/10.1378/CHEST.71.2_SUPPLEMENT.310

IF: 9.6

1977-02-01

Chest

Abstract:pulmonary arterial systolic blood pressures are also not increased during the first two weeks of monocrotaline treatment. Other changes in the arterial wall might include early myogenic, neural or hormonal influences predisposing to heightened muscular tone. The effect of DLpropranolol on the response to monocrotaline was examined in view of the f -adrenergic antagonism shown by the L-stereoisomer. In addition, both stereoisomers have local anesthetic properties, and inhibit calcium uptake by isolated sarcoplasmic reticulum with an ED5O of 10-4M.3 Therefore, propranolol decreases adrenergic activity and decreases calcium movement into the cell by both a direct and indirect action. Concurrent administration of propranolol prevented cardiac hypertrophy over the period of the experiment. It is unclear, however, whether the protective effect of propranolol in preventing cardiac hypertrophy is exerted on the heart or lungs. Initial examination of slides prepared from the lungs of propranolol-treated rats suggested that medial hypertrophy is not so marked; quantitative determination of medial thickness has not yet been done. Treatment with propranolol also lessened the increase in pulmonary arterial blood pressure caused by monocrotaline. This observation offers the opportunity to explore at which level propranolol is acting-capillary bed, muscular arteries, or heart-and by which of its several pharmacologic actions. This may provide a degree of insight into the mechanism of monocrotaline toxicity.